A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 1, 2011

Primary Completion Date

August 6, 2013

Study Completion Date

February 6, 2014

Conditions
Delayed Function of Renal Transplant
Interventions
DRUG

Eculizumab

1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion

DRUG

Placebo

240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion

Trial Locations (1)

10029

Mount Sinai Recanati/Miller Transplantation Institute, New York

Sponsors
All Listed Sponsors
collaborator

Alexion Pharmaceuticals, Inc.

INDUSTRY

lead

Schroppel, Bernd, M.D.

INDIV